SMN2 and proximal spinal muscular atrophy: For instance, Nusinersen, the first medication ever to be licensed by the FDA to treat SMA, works by attaching to the precursor mRNA created by the transcription of the SMN2 gene, changing the RNA splicing pattern, and subsequently enhancing the expression of normal SMN proteins (Finkel et al., 2021).